TY - JOUR
T1 - The use of Faecal Microbiota Transplantation (FMT) in Europe: A Europe-wide survey
AU - Baunwall, Simon Mark Dahl
AU - Terveer, Elisabeth M
AU - Dahlerup, Jens Frederik
AU - Erikstrup, Christian
AU - Arkkila, Perttu
AU - Vehreschild, Maria JGT
AU - Ianiro, Gianluca
AU - Gasbarrini, Antonio
AU - Sokol, Harry
AU - Kump, Patrizia K
AU - Satokari, Reetta
AU - De Looze, Danny
AU - Vermeire, Séverine
AU - Nakov, Radislav
AU - Brezina, Jan
AU - Helms, Morten
AU - Kjeldsen, Jens
AU - Rode, Anne A
AU - Kousgaard, Sabrina Just
AU - Alric, Laurent
AU - Trang-Poisson, Caroline
AU - Scanzi, Julien
AU - Link, Alexander
AU - Stallmach, Andreas
AU - Kupcinskas, Juozas
AU - Johnsen, Peter Holger
AU - Garborg, Kjetil
AU - Rodríguez, Eugenia Sánchez
AU - Serrander, Lena
AU - Brummer, Robert J
AU - Galpérine, Katerina Tatiana
AU - Goldenberg, Simon D
AU - Mullish, Benjamin H
AU - Williams, Horace RT
AU - Iqbal, Tariq H
AU - Ponsioen, Cyriel
AU - Kuijper, Ed J
AU - Cammarota, Giovanni
AU - Keller, Josbert J
AU - Hvas, Christian Lodberg
PY - 2021/10
Y1 - 2021/10
N2 - Background Faecal microbiota transplantation (FMT) is an emerging treatment modality, but its current clinical use and organisation are unknown. We aimed to describe the clinical use, conduct, and potential for FMT in Europe. Methods We invited all hospital-based FMT centres within the European Council member states to answer a web-based questionnaire covering their clinical activities, organisation, and regulation of FMT in 2019. Responders were identified from trials registered at clinicaltrials.gov and from the United European Gastroenterology (UEG) working group for stool banking and FMT. Findings In 2019, 31 FMT centres from 17 countries reported a total of 1,874 (median 25, quartile 10–64) FMT procedures; 1,077 (57%) with Clostridioides difficile infection (CDI) as indication, 791 (42%) with experimental indications, and 6 (0•3%) unaccounted for. Adjusted to population size, 0•257 per 100,000 population received FMT for CDI and 0•189 per 100,000 population for experimental indications. With estimated 12,400 (6,100–28,500) annual cases of multiple, recurrent CDI and indication for FMT in Europe, the current European FMT activity covers approximately 10% of the patients with indication. The participating centres demonstrated high safety standards and adherence to international consensus guidelines. Formal or informal regulation from health authorities was present at 21 (68%) centres. Interpretation FMT is a widespread routine treatment for multiple, recurrent CDI and an experimental treatment. Embedded within hospital settings, FMT centres operate with high standards across Europe to provide safe FMT. A significant gap in FMT coverage suggests the need to raise clinical awareness and increase the FMT activity in Europe by at least 10-fold to meet the true, indicated need. Funding NordForsk under the Nordic Council and Innovation Fund Denmark (j.no. 8056–00006B).
AB - Background Faecal microbiota transplantation (FMT) is an emerging treatment modality, but its current clinical use and organisation are unknown. We aimed to describe the clinical use, conduct, and potential for FMT in Europe. Methods We invited all hospital-based FMT centres within the European Council member states to answer a web-based questionnaire covering their clinical activities, organisation, and regulation of FMT in 2019. Responders were identified from trials registered at clinicaltrials.gov and from the United European Gastroenterology (UEG) working group for stool banking and FMT. Findings In 2019, 31 FMT centres from 17 countries reported a total of 1,874 (median 25, quartile 10–64) FMT procedures; 1,077 (57%) with Clostridioides difficile infection (CDI) as indication, 791 (42%) with experimental indications, and 6 (0•3%) unaccounted for. Adjusted to population size, 0•257 per 100,000 population received FMT for CDI and 0•189 per 100,000 population for experimental indications. With estimated 12,400 (6,100–28,500) annual cases of multiple, recurrent CDI and indication for FMT in Europe, the current European FMT activity covers approximately 10% of the patients with indication. The participating centres demonstrated high safety standards and adherence to international consensus guidelines. Formal or informal regulation from health authorities was present at 21 (68%) centres. Interpretation FMT is a widespread routine treatment for multiple, recurrent CDI and an experimental treatment. Embedded within hospital settings, FMT centres operate with high standards across Europe to provide safe FMT. A significant gap in FMT coverage suggests the need to raise clinical awareness and increase the FMT activity in Europe by at least 10-fold to meet the true, indicated need. Funding NordForsk under the Nordic Council and Innovation Fund Denmark (j.no. 8056–00006B).
KW - Faecal microbiota transplantation
KW - FMT
KW - Stool banking
KW - Clostridioides difficile
KW - Clostridioides difficile
KW - FMT
KW - Faecal microbiota transplantation
KW - Stool banking
U2 - 10.1016/j.lanepe.2021.100181
DO - 10.1016/j.lanepe.2021.100181
M3 - Journal article
C2 - 34693388
SN - 2666-7762
VL - 9
JO - The Lancet Regional Health - Europe
JF - The Lancet Regional Health - Europe
M1 - 100181
ER -